Chemoradiation-induced oral mucositis (CRIOM) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Oral mucositis is an important complication in non-surgical cancer treatments. It represents the major complication in radiotherapy of tumors located in head and neck areas. Mucositis manifests itself as erythema, edema, or ulceration that can be accompanied by a mild burning sensation. Radiation-induced mucositis may involve any radiation-exposed area, including the hard palate, lip, buccal mucosa, tongue ventrolateral aspect, and base of the mouth. The direct mechanisms of irradiation include interrupting the cell renewal cycle and apoptosis. The indirect mechanisms leading to oral mucositis include the release of inflammation mediators, the loss of protective salivary role, and neutropenia induced by the treatment.

·       Oropharyngeal mucositis occurs in more than 85 to 92% of patients who receive radiation and or chemotherapy for head and neck tumors.

·       According to the research, ~85% of patients undergoing radiation therapy showed oropharyngeal mucositis amongst which ~30% developed severe oropharyngeal mucositis.

The competitive landscape of Chemoradiation-induced oral mucositis (CRIOM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chemoradiation-induced oral mucositis (CRIOM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chemoradiation-induced oral mucositis (CRIOM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chemoradiation-induced oral mucositis (CRIOM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          EC-18   Enzychem Lifesciences Phase 2

Comments

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034